State Street’s Generate Biomedicines GENB Stock Holding History

State Street’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.88M	Buy	+526,565	New	+$7.17M	﹤0.01%	2743

Other funds holding GENB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

State Street's GENB Position: Q2 2026 in Review

State Street opened a new position in Generate Biomedicines (GENB) in Q2 2026: 526,565 shares worth $8.88M. The stake represents ﹤0.01% of the portfolio and ranks #2743 among its holdings.

25 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

State Street held 526,565 shares of Generate Biomedicines worth $8.88M as of Q2 2026.
Generate Biomedicines was a new State Street position in Q2 2026.
Generate Biomedicines made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2743 holding.
25 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.